N/A N=776 A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)
Non-melanoma Skin Cancer
Primary: Cure Rate — 751 lesions
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
Skin Cancer
Primary: Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease) — 14; 4; 19 participants
Phase 3 N=162 Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Actinic Keratosis · Warts · Basal Cell Carcinoma
Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120
Phase 2 N=12 Preventing Squamous Cell Skin Cancer
Squamous Cell Carcinoma of the Skin
Primary: Mean Number of Squamous Cell Carcinomas — 0.75; 1.00 # of squamous cell carcinomas — p=0.750
N/A N=33 Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: This is a Study to Measure the Efficacy of the Nd:YAG Laser to Cause Complete Regression of Basal Cell Carcinoma. — 28 tumors
Phase 2 N=39 Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma
Metastatic Skin Squamous Cell Carcinoma · Recurrent Skin Squamous Cell Carcinoma
Primary: Overall Response Rate — 3 Participants
Phase 2 N=18 The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants
Phase 4 N=954 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Carcinoma, Basal Cell · Carcinoma, Squamous Cell · Skin Neoplasms
Primary: The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed — 3.37; 3.52 years — p=0.93
Phase 3 N=120 Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma
Superficial Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT or Cryotherapy Cycle — 92; 90 percentage of…
Phase 3 N=102 Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle — 80 percentage of participants
Phase 2 N=15 Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
N/A N=54 Skin Care Behaviors Among Melanoma Survivors and Their Families
Melanoma
Primary: Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. — 24; 22; 2; 5 Participants
N/A N=13 Radiation Therapy in Treating Patients With Recurrent Breast Cancer
Breast Cancer
Primary: Ipsilateral Breast Tumor Recurrence Rates — 0; 0 percentage of participants
N/A N=81 Correlation Between Skin Carotenoid Levels and Previous History of Skin Cancer
Skin Cancer · Basal Cell Carcinoma · Squamous Cell Carcinoma
Primary: Skin Carotenoid Levels in Subjects With History of Squamous Cell Carcinoma Versus Control Subjects — 27,635; 31,219 Raman spectroscopy intensity counts — p=0.31
N/A N=75 Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients
Squamous Cell Carcinoma
Primary: Number of Control and Intervention Participants on Skin Self-examination Performance at Follow-up 1 Month After Intervention — 34; 8 Participants
Phase 2 N=10 Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
Breast Cancer · Breast Neoplasms
Primary: Objective Response (Complete Clinical Response+ Partial Response) — 20 percentage of patients
Phase 2 N=138 Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
Melanoma
Primary: Immunologic Response Rate — 7; 1; 0; 0 Participants
Phase 2 N=30 Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer
Skin Basal Cell Carcinoma
Primary: Overall Response Rate — 69.7 percentage of tumor lesions
Phase 3 N=450 Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Carcinoma, Squamous Cell
Primary: Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy — 53.3; 53.7 Months — p=0.07243
N/A N=148 ObservAtional Study to Investigate Surgical Site Infection in Ulcerated Skin Cancers
Skin Cancer
Primary: To Ascertain the Percentage of Surgical Site Infections Following Excision of Ulcerated Skin Tumours in Dermatology Departments. — 35 Participants
Phase 4 N=485 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
Actinic Keratosis (AK)
Primary: Incidence of SCC — 3.1; 0.4 percentage of subjects
Phase 4 N=86 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
Skin Neoplasms · Kidney Transplantation
Primary: New Biopsy-Confirmed Nonmelanoma Skin Cancer (NMSC) Lesions Per Subject Per Year — 1.31; 2.48 Standardized Yearly Rate of NMSC — p=0.022
N/A N=54 Enhancing Skin Cancer Early Detection and Treatment in Primary Care
Cutaneous Melanoma
Primary: Change in Clinician Knowledge in Melanoma Risk and Lesion Identification — 72.1; 80.8 score on a scale — p=0.05
N/A N=8 Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
Vulvar Cancer
Primary: Percentage of Participants With Clinical and Histologic Remission — 75 % of participants
Phase 2 N=23 Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
Recurrent Skin Cancer · Squamous Cell Carcinoma of the Skin
Primary: Early Progression Rate — 31.8 percentage of participants
Phase 2 N=104 Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
High-Risk Melanoma
Primary: Immunologic Response Rate — 2; 0; 0; 3 Participants
Phase 2 N=48 Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
Recurrent Head and Neck Cancer · Carcinoma, Squamous Cell of Head and Neck
Primary: Progression Free Survival — 7.9 months
N/A N=30 CellFX Treat & Resect Low-Risk BCC Feasibility Study
BCC - Basal Cell Carcinoma · BCC · Excision Margin
Primary: Number of Lesions With BCC Histological Clearance — 34 BCC Lesions
Phase 2 N=11 Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer
Recurrent Skin Carcinoma · Skin Squamous Cell Carcinoma
Primary: Response Rate of Pembrolizumab — 72.73 percentage of participants
N/A N=600 Skin Health Online for Melanoma: Better Risk Assessment
Melanoma (Skin)
Primary: Reach of Personalized Genomic Testing for Melanoma. — 0; 204; 0; 295 Participants